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Abstract 
Nociceptin/Orphanin FQ (N/OFQ) is an endogenous neuropeptide of 17 amino acids, related to 
opioid peptides but with its own receptor, distinct from conventional opioid receptors, the 
ORL1 or NOP receptor. The NOP receptor is a G protein-coupled receptor which activates Gi/o 
proteins and thus induces an inhibition of neuronal activity. The peptide and its receptor are 
widely expressed in the central nervous system with a high density of receptors in regions 
involved in learning and memory. This review describes the consequences of the 
pharmacological manipulation of the N/OFQ system by NOP receptor ligands on learning 
processes and on the consolidation of various types of long term memory. We also discuss the 
role of endogenous N/OFQ release in the modulation of learning and memory. Finally we 
propose several putative neuronal mechanisms taking place at the level of the hippocampus and 
amygdala and possibly underlying the behavioral amnestic or promnesic effects of NOP 
ligands. 
 
Keywords: Nociceptin/orphaninFQ, long term memory, hippocampus, amygdala, drug-
induced amnesia, promnesic compound.  
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1. Introduction 
 
Nociceptin, also called orphanin FQ, (N/OFQ) is an endogenous peptide involved in 
numerous physiological functions at the level of the nervous, cardiovascular, respiratory, 
gastrointestinal, urinary and immune systems (Lambert 2008). Its receptor, ORL1 for opioid-
receptor-like 1 or NOP, was first cloned by homology with opioid receptors (Mollereau et al. 
1994). It is a G-protein coupled receptor of the rhodopsin family that has very strong 
homologies with classical mu (MOP), delta (DOP) and kappa (KOP) opioid receptors. 
However, it has a very low affinity for conventional opioid ligands such as morphine or 
enkephalins which initially made it an orphan receptor. A 17 amino acid peptide corresponding 
to N/OFQ was soon purified from rat and pig brain (Meunier et al. 1995; Reinscheid et al. 
1995). The discovery of this system is therefore one of the first examples of reverse 
pharmacology. The peptide is very similar, in terms of sequence and charge, to the endogenous 
KOP agonist dynorphin A. It is derived from a protein precursor capable of releasing other 
peptides whose function remains unknown (Mollereau et al. 1996). The binding of N/OFQ to 
the NOP receptor leads to the activation of Gi/o inhibitory G proteins, with consequent 
inhibition of adenylyl cyclase and voltage-gated calcium channels, and activation of GIRK 
(inwardly rectifying) potassium channels (New and Wong 2002).   
The development of ligands specific for the NOP receptor made it possible to study in 
preclinical models the major physiological functions and pathologies in which it is involved. 
At the level of the nervous system, the most promising, in terms of therapy, are the following 
(Lambert 2008): pain, drug dependence, Parkinson's disease, anxiety, depression and memory. 
Indeed the NOP receptor has a very wide distribution in the central nervous system (Mollereau 
and Mouledous 2000). It is present in the cortex, the thalamus, the limbic system (including the 
hippocampus (HPC), the septum, the nucleus of the stria terminalis (BNST), the amygdaloid 
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complex, the hypothalamus, and monoaminergic nuclei (raphe nucleus, locus coeruleus, ventral 
tegmental area, substantia nigra). The neurons producing the precursor have a slightly more 
restricted distribution (Reinscheid et al. 2000), with strong expression in the BNST, the medial 
pre-optic area, the lateral septum and the medial and central amygdala (CeA). This distribution 
strongly suggests a role of the N/OFQ system at the interface between the control of stress and 
emotions (Fulford 2015; Gavioli and Calo 2013; Witkin et al. 2014) and memory processes 
(Andero 2015; Noda et al. 2000; Ouagazzal 2015) that are the main focus of this review article.  
 
2. Pharmacological modulation of learning and memory by NOP agonists 
 
2.1  N/OFQ affects different types of long-term memory 
 The first study on the effect of N/OFQ on memory was performed in rats and focused 
on spatial memory. It showed that the intra-hippocampus administration (in the CA3 region) of 
10 nmol of the peptide almost completely blocked the acquisition in the Morris Water Maze 
(MWM) (see Table 1 for a description of the behavioral paradigms). However, the possibility 
of confounding effects, notably related to a disturbance of the exploratory behavior of the 
animal by the peptide, was not totally ruled out (Sandin et al. 1997). It was subsequently shown 
that a lower dose of 3.3 nmol injected into the HPC produced the same inhibition of learning 
without negative effect on exploration (Sandin et al. 2004). Normal learning in the visible 
platform version of the test also enabled the authors to rule out other confounding effects related 
to sensory perception or motivation. In addition, the co-administration of the NOP antagonist 
[Nphe1]N/OFQ(1–13)-NH2 (Calo et al. 2000) showed that this deleterious action on spatial 
learning was indeed mediated by the NOP receptor (Redrobe et al. 2000). The same negative 
impact on memory acquisition, specifically in the spatial version of the MWM, was observed 
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in mice at doses of 5 and 10 nmol after intra-cerebroventricular (icv) and 1 nmol after intra-
CA3 injection (Kuzmin et al. 2009). Here again the consequences of N/OFQ injection were 
prevented by the administration of the [Nphe1]N/OFQ(1–13)-NH2 antagonist.  
 Other types of memory are also affected by the icv or intra-cerebral administration of 
the peptide. This was the case for contextual memory in the contextual fear conditioning test 
(CFC) for icv doses of 0.01 to 1 nmol in mice (Mamiya et al. 2003) and 1 to 2.5 nmol in rats 
(Fornari et al. 2008). The latter study also demonstrated that this amnestic effect was not due to 
a phenomenon of state dependence, meaning an integration of the interoceptive properties of 
the drug in the memory trace, since the memory was not restored when the test was performed 
in the presence of N/OFQ. On the other hand, N/OFQ was shown to be less active in the tone 
fear conditioning (TFC) paradigm (Mamiya et al. 2003) except at high dose (5 nmol) in rats 
(Fornari et al. 2008). Inhibitory avoidance (IA) is another aversive memory paradigm in which 
animal performances are affected by N/OFQ. In mice, 0.5 to 5 nmol administered icv during 
the acquisition produced a decrease in the step-down latency during the retention test 
(Hiramatsu and Inoue 1999). A similar effect was observed for a dose of 0.5 nmol in the step-
through version of the test in rats, this amnestic action being blocked by the co-administration 
of 1 nmol of [Nphe1]N/OFQ(1–13)-NH2 (Hiramatsu et al. 2008). Moreover icv doses of 1 and 
4 nmol delayed the acquisition in a multi-trial version of IA in mice, and this effect was again 
prevented by [Nphe1]N/OFQ(1–13)-NH2 (Liu et al. 2007). Signs of amnesia were also observed 
when the inhibitory avoidance phenomenon was evaluated in the elevated T-maze test (Asth et 
al. 2015). In rats, N/OFQ has also been injected intra-basolateral amygdala (BLA) in an IA 
paradigm, and doses of 1 to 100 pmol have been shown to negatively affect memory retention 
performance (Roozendaal et al. 2007). The last type of memory on which the effect of N/OFQ 
has been tested is recognition memory. In the mouse object recognition (OR) test, the peptide 
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injected icv (from 1 nmol) or intra-HPC (3 nmol, dorsal HPC) before learning induced memory 
deficits when retention was evaluated 24h later (Goeldner et al. 2008).  
 2.2 Amnestic effects of systemic administration of NOP agonists 
 Since the discovery of the N/OFQ system, several small systemically active NOP 
receptor agonists have been identified (Toll et al. 2016; Zaveri 2003). In the context of learning 
and memory, the vast majority of studies have been based on systemic administration of the 
NOP agonist Ro 64-6198 [(1S, 3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-
1,3,8-triazaporo[4.5]decan-4-one], a compound developed by Roche (Wichmann et al. 2000). 
Overall, all the effects of icv administration of N/OFQ described above could be reproduced in 
rodents by intraperitoneal (ip) administration of Ro 64-6198 in a dose ranging from 0.3 to 3 
mg/kg. Specifically, in mice, the compound impaired spatial learning in the MWM (Higgins et 
al. 2002; Kuzmin et al. 2009), fear conditioning to the context, but not to the tone (including in 
an immediate shock deficit paradigm which eliminates a possible confounding role of the 
anxiolytic properties of the NOP agonist) (Goeldner et al. 2009), learning in inhibitory 
avoidance (only at high dose) (Adem et al. 2017), as well as object recognition memory 
(Goeldner et al. 2008).  
 It is worth noting that the interpretation of the results obtained with Ro 64-6198 is 
complicated by the appearance of a sedative action for high doses with an impairment in motor  
performances (Jenck et al. 2000). This confounding effect has been excluded in some studies, 
for example by showing that learning was unaltered in the visible platform version of the MWM 
(Higgins et al. 2002; Kuzmin et al. 2009), or that short term memory was unaffected in the 
object recognition test (Goeldner et al. 2008). Beyond this putative nonspecific neurological 
impairment, it must also be taken into account that the selectivity of Ro 64-6198 for the NOP 
receptor is not optimal and that it interacts in particular, although with a 100-fold lower affinity, 
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with the other members of the opioid receptor family (Jenck et al. 2000). Thus the inhibitory 
effect of the compound at 3 mg/kg in IA learning were not blocked by the [Nphe1]N/OFQ(1–
13)-NH2 antagonist (Adem et al. 2017). Overall, it can be concluded that the effective doses are 
slightly higher than the doses producing anxiolytic effects and slightly lower than those 
provoking sedation (Jenck et al. 2000; Varty et al. 2005), indicating a relatively narrow 
therapeutic window for the amnestic action of the reference small molecule NOP agonist. It is 
therefore necessary to continue to improve the catalog of small NOP receptor agonist 
molecules, especially in terms of selectivity. In this framework, a recent study using the new 
compound SR-8993 (3 mg/kg ip) in the fear conditioning paradigm gave results partially in 
agreement with the reported effects of Ro 64-6198. Like the latter, SR-8993 inhibited context 
conditioning but contrary to Ro 64-6198 it also attenuated tone conditioning (Andero et al. 
2013). This latest report also showed that the amnestic properties of the NOP agonist were 
conserved in a mouse model of dysregulated fear (Andero et al. 2013). 
 2.3 Different phases of long-term memory can be targeted 
 In most of the studies mentioned so far treatment with NOP agonists was carried out 
before learning and it was therefore difficult to know whether the amnestic effects observed 
were due to an inhibition of memory acquisition (encoding), consolidation (stabilization of the 
memory trace) or both. In the paradigms based on multiple trial learning like the MWM, it has 
been clearly demonstrated that the activation of NOP receptors interferes with the acquisition 
phase of the task (Higgins et al. 2002; Kuzmin et al. 2009; Redrobe et al. 2000; Sandin et al. 
2004). This inhibition of acquisition could be linked to a perturbation of spatial working 
memory. Indeed, icv administration of 0.5 to 5 nmol of N/OFQ decreased the performances, 
evaluated by spontaneous alternation, in the Y-maze (Hiramatsu and Inoue 1999). Similarly, 
using a multi-trial IA protocol, it was shown that icv N/OFQ delayed the acquisition of the task 
in mice (Liu et al. 2007). For the other paradigms for which NOP agonists have been tested the 
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data suggest also an impairment of the memory consolidation phase. N/OFQ injected icv in 
mice after conditioning inhibited long-term memory retention in FC (Mamiya et al. 2003). The 
SR-8993 and Ro 65-6570 agonists also exhibited amnestic properties in FC when administered 
immediately after conditioning (Andero et al. 2013; Rekik et al. 2017). Similarly in IA in rats, 
intra-BLA injection of 1 to 100 pmol of N/OFQ immediately or 3h (but not 6h) post-training 
impaired retention performance (Roozendaal et al. 2007). Finally, in the mouse OR paradigm, 
pretreatment with Ro 64-6198 disrupted the long-term memory tested 24 hours after learning 
but did not affect the short-term memory tested at 3 hours, which also suggests an action on the 
consolidation phase (Goeldner et al. 2008). It therefore seems that, depending to the type of 
memory considered, systemic or central activation of NOP receptors may interfere with the 
acquisition phase of memory, especially in spatial tasks and/or in procedures based on multi-
trial learning, or with its consolidation, especially for aversive and recognition memory. 
 The effects of NOP receptor activation on the later phases of long-term memory 
processes have been poorly studied. At doses known to affect the acquisition or consolidation 
processes, the agonists Ro 64-6198 and Ro 65-6570 did not inhibit memory retrieval in the 
object recognition and contextual fear conditioning paradigms respectively in mice (Goeldner 
et al. 2008; Rekik et al. 2017). Under certain circumstances, memory retrieval can cause a 
destabilization of the memory trace. The memory must then go through a process called 
reconsolidation to be stabilized again over time (Alberini and Ledoux 2013; Nader 2015). It has 
recently been shown that NOP agonists administered immediately after memory reactivation 
inhibit the reconsolidation of contextual fear memory in mice (Rekik et al. 2017). This effect 
was produced by both N/OFQ (3 nmol icv) and small molecule agonists Ro 65-6570 (1 mg/kg 
ip) and AT-403 (0.1 mg/kg ip), a recently discovered compound showing a high affinity and 
selectivity for NOP receptors (Ferrari et al. 2017). On the other hand, at the same doses, the two 
small agonist molecules were ineffective in interfering with the reconsolidation of tone fear 
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memory suggesting that, as with fear memory consolidation, NOP receptor activation is more 
effective in interfering with contextual than cued fear memory reconsolidation (Rekik et al. 
2017).  
 2.4 Promnesic effects of NOP agonists 
 Some studies have shown that very low doses of icv N/OFQ (10-100 fmol) could prevent 
the deleterious action of scopolamine in models of working memory (spontaneous alternation 
in Y-maze) and IA (Hiramatsu and Inoue 2000). Such promnesic effects have even been 
reported for doses as low as 1 fmol after intra-HPC injection (Miwa et al. 2009). However, it 
has since been shown that these properties were not mediated by the NOP receptor as they 
persisted in receptor KO mice, and the involvement of a metabolite of the peptide has been 
suggested (Miwa et al. 2010).  
 Other reports have demonstrated biphasic effects of icv (Adem et al. 2017) and intra-
HPC (Sandin et al. 2004) injection of N/OFQ. Thus, contrary to the amnestic actions obtained 
for the 3.3 nmol intra-HPC dose in rats, intermediate doses of 0.33 to 1 nmol facilitated learning 
in the MWM  (Sandin et al. 2004). In addition, these promnesic effects were reversed by a NOP 
antagonist. Similarly in mice, it has been recently shown that icv administration of 1 or 10 nmol 
of N/OFQ inhibited performance in the IA test, but that the 0.01 nmol dose had a facilitating 
role (Adem et al. 2017). Thus, even though the majority of studies suggest that intermediate 
doses of NOP agonist are inactive in learning and memory paradigms, the above-mentioned 
work encourages further investigation of potential promnesic consequences of NOP receptor 
activation. 
 
3. Modulation of learning and memory by endogenous N/OFQ  
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 In view of the amnestic effects produced by the administration of NOP receptor agonists, 
it may be proposed that under certain circumstances the release of endogenous N/OFQ could 
inhibit learning and memory processes. A set of data from the study of NOP receptor or peptide 
precursor knockout (KO) mice suggest that this is indeed the case.  
 3.1 Evidence from the study of receptor or precursor KO mice 
 The first constitutive NOP receptor knockout (NOP(-/-)) mouse line showed enhanced 
performances in terms of learning and memory. On the one hand memory acquisition was 
facilitated in the MWM test, NOP(-/-) mice learning faster than the NOP(+/+) mice, but 
showing no improvement in terms of retention of the spatial memory (Manabe et al. 1998). 
Similarly, in a KUROBOX system that makes it possible to test spatial learning with less stress 
than MWM, NOP(-/-) performed better than NOP(+/+) mice (Nagai et al. 2007). On the other 
hand, it is the memory retention that was increased in IA, with NOP(-/-) mice showing extended 
retention time compared to NOP(+/+) mice (Manabe et al. 1998). In the same way, in fear 
conditioning, contextual memory (but not the association of the electric shock with an auditory 
cue) was more durable in NOP(-/-) mice (Mamiya et al. 2003). Also, in the water-finding test, 
the same mouse line showed an enhancement of latent learning, compared to NOP(+/+) mice, 
that might be related to a decrease in dopamine content in the frontal cortex (Mamiya et al. 
1998). Finally, NOP(-/-) mice showed no working memory improvement when evaluated by 
the alternation behavior in the Y-maze (Mamiya et al. 1999). 
 In contrast to the NOP KO (Manabe et al. 1998), the first study of ppN/OFQ precursor 
KO (ppN/OFQ(-/-)) mice showed that they had wild type-like performances in the MWM 
(Koster et al. 1999). This discrepancy could be due to differences in the genetic background of 
the two lines or to a ceiling effect linked to differences in task difficulty between the two studies. 
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It is also possible that the lack of performance improvement was due to the anxious phenotype 
of the ppN/OFQ(-/-) line, which is not observed in NOP(-/-) mice in the EPM test (Mamiya et 
al. 1998). Indeed, ppN/OFQ(-/-) mice showed abnormalities of response and adaptation to stress 
(Koster et al. 1999). These phenotypic differences between receptor and precursor KO mice 
could be linked to the deletion of the other two peptides present in the precursor sequence and 
whose target and function remain elusive (Mollereau et al. 1996). Anyway subsequent studies 
have managed to highlight an improvement in learning and memory processes in ppN/OFQ(-/-
)  lines. The same OFQ/N peptide deficient mice showed improved acquisition of the water 
maze task provided that the mice where single-housed, thus reducing chronic social stress 
(Higgins et al. 2002). ppN/OFQ(-/-)  animals also performed better during reversal training in 
the MWM (Kuzmin et al. 2009). In terms of aversive memory, mice showed an increase in 
memory retention in FC and IA (Adem et al. 2017; Higgins et al. 2002), which is consistent 
with the NOP(-/-) mouse phenotype (Mamiya et al. 2003; Manabe et al. 1998).  
 The results obtained with the KO lines for the peptide or the receptor are globally 
consistent with the hypothesis of an inhibitory role of the N/OFQ system on various forms of 
learning and long-term memory. The study of constitutive KO, however, does not exclude the 
involvement of developmental adaptations in these animals and makes it difficult to identify 
the temporal phase of learning that is affected by the absence of receptor or peptide (learning 
rate vs memory retention). It is also possible that some of the apparent promnesic effects 
observed in constitutive KO mice do not result from a direct improvement of memory 
processes. A general increase in the level of arousal of the animals could for example indirectly 
increase acquisition and retrieval performances. The generation of conditional mutant mice 
could help addressing these questions. These limitations of genetic models can also be 
overcome by the use of pharmacological approaches based on NOP antagonists. 
 3.2 Evidence from the study of the effect of NOP antagonists  
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 There are very few studies specifically designed to test the promnesic properties of NOP 
antagonists. In the majority of cases, the antagonists were used to reverse the amnestic effects 
of NOP agonists and thus to demonstrate that these properties were specific for the NOP 
receptor. These reports, however, included a control group treated by the antagonist alone and 
in the vast majority of cases this treatment is shown to have no effect on learning and memory. 
This was for example the case for the [Nphe1]N/OFQ(1–13)-NH2 antagonist at the dose of 50 
nmol intra-HPC in rats (Redrobe et al. 2000) and 10 nmol icv in mice (Kuzmin et al. 2009) on 
memory acquisition in the MWM. Similarly 10 nmol of [Nphe1]N/OFQ(1–13)-NH2 icv in mice 
did not improve  acquisition in IA (Liu et al. 2007). Another antagonist, UFP-101 (Calo et al. 
2002), at the dose of 5 nmol intra-HPC did not improve performances in the OR paradigm 
(Goeldner et al. 2008). On the contrary, it has been shown in the rat that post-training intra-
BLA injection of 10 pmol of [Nphe1]N/OFQ(1–13)-NH2 increased memory retention in IA 
(Roozendaal et al. 2007). In addition, preliminary results suggested that the J-113397  
antagonist (Kawamoto et al. 1999) ip at doses of 3 and 10 mg/kg in mice favored contextual 
learning in the immediate shock deficit paradigm and improves spontaneous alternations 
reflecting spatial working memory in the Y-maze (Ouagazzal 2015). The study of NOP 
antagonists therefore only partly confirms the hypothesis suggested by the characterization of 
KO mice, namely the possibility of improving memory performance by blocking the N/OFQ 
system. It must be emphasized, however, that most of the studies cited above were not aimed 
at the validation of the promnesic properties of NOP antagonists. In most cases, for example a 
single dose has been tested. In addition, the high performance of untreated control groups leaved 
little room for improved learning or memory retention in these studies. It seems therefore 
important to characterize further the potential promnesic effects of NOP antagonists, 
particularly in models in which the learning and memory capacities are altered.  
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4. Sites and mechanisms of action associated with the modulation of 
learning and memory by the N/OFQ system 
 
 The N/OFQ system presents such a wide distribution in the brain that its effects on 
memory are probably mediated by a multitude of mechanisms involving many regions such as 
the hippocampus, the extended amygdala, the prefrontal cortex, some aminergic nuclei, some 
thalamic nuclei, the habenula (Gavioli and Calo 2013; Mollereau and Mouledous 2000; Witkin 
et al. 2014). In the following chapter we will focus on the direct actions of the peptide in two 
regions which are key for the types of long term memory that have been discussed in the 
previous sections, namely the hippocampus and the amygdala. 
 4.1 The N/OFQ system in the hippocampus 
 The hippocampus is probably a major site of action of the N/OFQ system for the 
modulation of learning and memory as evidenced by the amnestic effects of intra-HPC N/OFQ 
injections described above (Goeldner et al. 2008; Kuzmin et al. 2009; Sandin et al. 1997; Sandin 
et al. 2004). Numerous N/OFQ-containing interneurons are found in the dentate gyrus (DG) 
and CA1, CA2 and CA3 sub-regions of the rodent hippocampus (Ikeda et al. 1998; Neal et al. 
1999b). By contrast the NOP receptor is expressed primarily on principal neurons in this area 
(Neal et al. 1999a). [3H]N/OFQ binding to rat and mouse brain sections is high in the stratum 
radiatum and oriens of the CA1 field, and moderate in the corresponding areas of the CA3 
region and the DG molecular layer. It is much lower in the pyramidal and granular, and in the 
lacunosum moleculare layers (Higgins et al. 2002). This inhibitory system is therefore ideally 
placed to negatively modulate transmission and synaptic plasticity at the major relays of the 
hippocampal circuit. 
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 Thus, on slices of rat DG, N/OFQ has been shown to inhibit synaptic transmission at the 
level of the lateral perforant path-granule cell synapse by a mechanism involving post-synaptic 
hyperpolarization linked to activation K+ currents (Yu and Xie 1998). The peptide also inhibited 
the induction of long-term potentiation (LTP) by the high frequency stimulation of the lateral 
perforant path as well as the NMDA receptor-mediated excitatory post-synaptic currents 
(EPSCs) evoked by stimulation of this pathway. Here again the phenomenon seems post-
synaptic since N/OFQ attenuated the inward currents evoked by focal application of NMDA 
(Yu and Xie 1998). N/OFQ induced changes in synaptic strength may actually be bi-directional 
since, at the same synapse in the mouse, another study has shown that the peptide also inhibited 
depotentiation and NMDA-dependent long-term depression (LTD) (Wei and Xie 1999).  
 In the principal cells of the CA3 region of the hippocampus, N/OFQ inhibited N, L and 
P/Q type voltage-gated calcium channels (Knoflach et al. 1996) et activated GIRK type 
potassium channels (Ikeda et al. 1997). In rat CA3 slices, the peptide showed inhibitory actions 
on epileptiform activity, with both presynaptic and postsynaptic sites of action (Tallent et al. 
2001). In particular, it inhibited EPSCs generated by stimulation of mossy fibers but also 
associational/commissural fibers. At the post-synaptic level the increase of K+ currents moved 
neurons away from their threshold for firing. But, unlike in the DG, presynaptic actions were 
also demonstrated, with a decrease in the frequency of miniature EPSCs (Tallent et al. 2001).  
 Finally, N/OFQ also increased K+ currents in the principal cells of the CA1 region of 
the rat hippocampus (Madamba et al. 1999) and could therefore interfere with pyramidal cell 
activation and synaptic plasticity in this area. It is in fact at the Schaffer collateral/CA1 synapse 
that the electrophysiological properties of N/OFQ have been studied the most, especially by 
comparing the effects of the exogenous application of N/OFQ to those produced by the release 
of endogenous peptide. In rat hippocampal slices, exogenous N/OFQ inhibited synaptic 
transmission at the Schaffer collateral/CA1 level, probably by a presynaptic mechanism, as 
16 
 
suggested by the increased paired-pulse facilitation (Yu et al. 1997). Another study also showed 
potentiation of feed-forward inhibition at the same synapse (Gutierrez et al. 2001). Subsequent 
work in the mouse also showed a depression of evoked population spikes but suggested a post-
synaptic mechanism related to hyperpolarization of pyramidal cells via GIRK channel 
activation (Bongsebandhu-phubhakdi and Manabe 2007; Higgins et al. 2002). Regarding LTP, 
studies in rats and mice showed an inhibition of NMDA-dependent LTP induced by theta burst-
type high frequency stimulations by exogenous N/OFQ (Higgins et al. 2002; Yu et al. 1997). 
This inhibition could be due to the hyperpolarization phenomena described above but could 
also involve a more direct regulation of NMDA receptor activity and signaling, and in particular 
an inhibition of kinases such as CamKII (Mamiya et al. 2003) and ERK (Goeldner et al. 2008). 
The role of endogenous N/OFQ was first studied in NOP(-/-)mice. In these animals, LTP 
induced by 100 Hz high-frequency tetanic stimulation of Schaffer collaterals was favored 
(Manabe et al. 1998). A subsequent study confirmed these results by showing that it was a form 
of NMDA-dependent LTP. The increase in LTP in these KO mice was probably of postsynaptic 
origin and was not found for lower frequency stimulation trains (20 and 50 Hz) (Taverna et al. 
2005). Bongsebandhu-phubhakdi and Manabe subsequently confirmed these results by 
showing an increase in 100 Hz tetanic stimulation induced LTP produced by the antagonist 
UFP-101 (Bongsebandhu-phubhakdi and Manabe 2007). In this case, UFP-101 opposed the 
inhibitory action of endogenous N/OFQ released at least in part from enkephalin-sensitive 
GABAergic interneurons. In contrast, no effect of the antagonist on basal synaptic transmission 
was demonstrated, suggesting the absence of basal N/OFQ tone. It is also interesting to note 
that UFP-101 did not affect theta burst induced LTP suggesting that there was no N/OFQ 
release under these conditions of Schaffer collateral stimulation (Bongsebandhu-phubhakdi and 
Manabe 2007).  
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 Overall, all of these investigations on hippocampus slices allow to draw several 
conclusions: 1) exogenous N/OFQ inhibits synaptic transmission and NMDA-dependent LTP 
by hyperpolarizing all types of principal cells, 2) the contribution of a presynaptic site of action 
is variable depending on the synapse and the species considered, 3) endogenous N/OFQ may 
have similar inhibitory effects, but it appears to be released only under particular stimulation 
conditions. Points 1 and 2 agree with the above behavioral data showing inhibitory actions of 
intra-HPC injection of N/OFQ on learning and memory (Goeldner et al. 2008; Kuzmin et al. 
2009; Sandin et al. 1997; Sandin et al. 2004) and synergistic effects between the peptide and an 
NMDA antagonist (Goeldner et al. 2009; Goeldner et al. 2008). Point 3 implies that it will be 
very important to better characterize the physiological and pathological conditions of N/OFQ 
release in the hippocampus to identify the circumstances under which NOP antagonists might 
exert promnesic effects. 
 By acting mainly on the principal cells in the HPC, N/OFQ differs from conventional μ 
and δ opioids, which act indirectly by inhibiting GABAergic transmission (Bramham and 
Sarvey 1996). However, N/OFQ could still have an indirect mechanism of action but rather via 
the regulation of the release of cholinergic or monoaminergic mediators (Schlicker and Morari 
2000). In this context, at the level of the hippocampus, only the modulation by N/OFQ of 
cholinergic signaling and its role in memory has been studied. Thus, it has been reported that 
N/OFQ inhibited the efflux of [3H]choline on electrically stimulated rat hippocampal slices 
(Cavallini et al. 2003) and that the icv injection of 0.5 nmol of the peptide induced a sharp fall 
in acetylcholine release in the rat HPC (Hiramatsu et al. 2008). In addition, NOP KO mice had 
an increased baseline level of acetylcholine in the hippocampus, associated with enhanced 
(higher power) theta rhythms during wake and REM sleep (Uezu et al. 2005). However, at the 
behavioral level, no synergy could be demonstrated between the amnestic effects of N/OFQ 
and the cholinergic nicotinic receptor antagonist, mecamylamine, nor with the muscarinic 
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receptor antagonist, scopolamine in the object recognition test, which suggests that the two 
systems do not interact in this paradigm (Reiss et al. 2012). Further studies will be needed to 
demonstrate a possible contribution of inhibition of acetylcholine release to the amnestic 
properties of the peptide in spatial and contextual memory paradigms. 
 A final way by which the hippocampal N/OFQ system could affect learning and memory 
is through the modulation of structural plasticity processes, i.e. adult neurogenesis in the DG or 
the plasticity of mature neurons. This hypothesis has not been studied in detail yet, but some 
indications suggest that it could be valid. Work done in vitro on primary cultures of embryonic 
hippocampal neurons produced conflicting results. Initially one study showed a positive effect 
of N/OFQ on the number and length of dendrites (Ring et al. 2006). On the contrary Alder et al 
have described more recently an inhibitory action of exogenous N/OFQ on dendritic growth, 
via an enhancement of the activity of RhoA, a small GTPase involved in cytoskeleton regulation 
(Alder et al. 2013). In vivo data are in agreement with this inhibitory effect of the peptide. Thus, 
an increase in the length of the primary dendrites and the number of spines of the granular cells 
of the DG was observed in ppN/OFQ(-/-) mice (Alder et al. 2013). In addition, a recent study 
has shown that repeated administration of the antagonist UFP-101 was able to increase the 
number of immature neurons positive for doublecortin in the DG of rats under chronic stress 
(Vitale et al. 2017). It can therefore be suggested that endogenous N/OFQ has a negative impact 
on the structural plasticity of mature neurons, but also on the generation of new neurons in the 
adult DG that contribute to spatial memory (Marin-Burgin and Schinder 2012).  
 N/OFQ therefore has negative effects on neuronal excitability and synaptic plasticity in 
the hippocampus. Its mechanism of action is not fully elucidated but may involve pre-synaptic 
inhibition of glutamate release and post-synaptic hyperpolarization, both processes being 
characteristic of Gi-coupled receptors. Finally the influence of N/OFQ on adult neurogenesis at 
the DG level and more generally on neuronal structural plasticity deserves further investigation. 
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 4.2 The N/OFQ system in the amygdala 
 Concerning the N/OFQ-sensitive aversive memory paradigms (FC, IA), the key region 
is the amygdala and in particular the basal and lateral nuclei (BLA) and the central nucleus 
(CeA). The BLA is the brain region where the processes of plasticity underlying emotional 
associative memory take place (association between the unconditioned stimulus, here the 
electric shock, and the conditioned stimulus, here the context or the tone) whereas the CeA is 
rather an output structure triggering conditioned behaviors (Johansen et al. 2011). The BLA 
and CeA contain N/OFQ labelled cell bodies and fibers (Neal et al. 1999b) and the NOP 
receptor is expressed in both regions (Neal et al. 1999a). As already mentioned systemic or icv 
administration of NOP agonists was more efficient in inhibiting the acquisition, consolidation 
and reconsolidation of hippocampus-dependent contextual aversive memory than that of 
amygdala-dependent cue aversive memory (Fornari et al. 2008; Goeldner et al. 2009; Mamiya 
et al. 2003; Rekik et al. 2017). However two studies have reported amnestic effects of intra-
amygdala injection of NOP ligands. In the rat, in the IA paradigm, 1 to 100 pmol of N/OFQ 
administered in the BLA post-training impaired retention performance (Roozendaal et al. 
2007). On the contrary, N/OFQ injection in the CeA was inactive. In the same report, it was 
show that intra-BLA administration of the NOP antagonist [Nphe1]N/OFQ(1–13)-NH2 
increased memory performances and that this improvement was prevented by atenolol (an 
antagonist of the 1-adrenergic receptor) (Roozendaal et al. 2007). This result suggests that 
endogenous N/OFQ prevents aversive memory consolidation by interfering with noradrenalin 
(NA) signaling. The second study, using the TFC paradigm in mice, demonstrated that intra-
CeA injection of the new NOP agonist SR-8993 inhibited memory consolidation (Andero et al. 
2013). This data contrasts with the lack of effect of intra-CeA injection of N/OFQ reported by 
Roozendaal (Roozendaal et al. 2007). This apparent discrepancy could be explained by 
differences in species and behavioral paradigms or by the relatively high dose used in the mouse 
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study that might have allowed diffusion of the drug from the CeA to the BLA. In any case, 
these behavioral data are in good agreement with the cellular actions of the peptide that have 
been described in this brain region. Similarly to the hippocampus both pre and post-synaptic 
actions have been reported. In rat brain slices, N/OFQ diminished evoked EPSCs in CeA 
neurons by a pre-synaptic mechanism (Kallupi et al. 2014). Moreover the opposite effect of the 
NOP antagonist [Nphe1]N/OFQ(1–13)-NH2 suggested that endogenous N/OFQ may tonically 
regulate basal spontaneous CeA glutamatergic activity (Kallupi et al. 2014). N/OFQ was also 
shown to inhibit pre-synaptically GABAergic synaptic transmission in CeA neurons (Roberto 
and Siggins 2006). Finally, also in the rat, N/OFQ hyperpolarized a fraction of CeA neurons 
projecting to the  periaqueductal grey by enhancing an inwardly rectifying potassium 
conductance (Chen et al. 2009). A similar spectrum of actions has been described in the rat 
BLA with a partial suppression of evoked EPSCs and inhibitory post-synaptic currents (IPSCs) 
as well as spontaneous miniature EPSCs and IPSCs (Meis and Pape 2001), and a reduction of 
the excitability of the majority of class I projecting cells (Meis and Pape 1998). Besides 
glutamatergic and GABAergic transmission, and in agreement with the behavioral study cited 
above (Roozendaal et al. 2007), the modulation of the release of NA by the N/OFQ system has 
been described. Local infusion of the peptide in the BLA decreased NA levels measured by 
microdialysis by around 30% whereas systemic administration of the NOP antagonist J-113397 
doubled basal levels of the adrenergic transmitter (Kawahara et al. 2004). 
 
5. Conclusion – Future directions 
 
 Both exogenous and endogenous N/OFQ clearly has a negative impact on learning and 
memory. These impairments appear to mainly affect context-dependent learning, to involve 
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multiple regions including the HPC and the BLA, and to be mediated through pre- and post-
synaptic inhibition of NMDA and noradrenergic signaling. So far three types of long term 
memory have been investigated: spatial memory in the MWM, aversive memory in the FC and 
IA paradigms and recognition memory in the OR test. Therefore an outstanding issue is the 
generality of the involvement of NOP receptor function in various forms of learning. Given its 
wide distribution the NOP receptor could be involved in a number of memory-related brain 
functions, not limited to hippocampus-dependent memory. Thus two forms of memory deserve 
further investigation, in particular because they have a major therapeutic interest. The first one 
is short-term memory and especially working memory. Studies suggest that N/OFQ could 
disrupt working memory evaluated by spontaneous alternation in the Y-maze (Hiramatsu and 
Inoue 1999) and delayed matching or delayed nonmatching to position tasks (Higgins et al. 
2002) but the active doses are relatively high. This work should be completed to better 
characterize these effects and in particular their specificity. Similarly preliminary data suggest 
that the administration of NOP antagonists may favor working memory (Ouagazzal 2015) but 
here again more research is needed. The second form of memory for which the role of the 
N/OFQ system remains to be characterized is reward memory. The peptide was shown to 
prevent the development of conditioned place preference induced by abuse drugs such as 
opioids, stimulants and alcohol (Zaveri 2011). This inhibitory effect was proposed to be due to 
the anti-reward properties of the system. Indeed N/OFQ has been shown to reduce morphine- 
and cocaine-induced release of dopamine in the nucleus accumbens (Di Giannuario et al. 1999; 
Lutfy et al. 2001). However, in order to develop a place preference, the animals have to learn 
the association between the rewarding properties of the drug and the context in which the drug 
is experienced. It is therefore possible that part of the inhibitory effect of N/OFQ in this task is 
due to an attenuation of associative contextual memory. NOP agonists could thus be useful to 
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decrease the rewarding properties of drugs of abuse but also to weaken maladaptive drug-
associated memories that can promote relapse (Milton and Everitt 2012). 
 This last point brings us to the question of the therapeutic perspectives of the N/OFQ-
NOP receptor system in the field of learning and memory. Autoradiographic localization of 
N/OFQ binding sites in macaque brain demonstrated that similarly to rodents the NOP receptor 
is highly expressed in the hippocampus and the amygdala in primates, suggesting a conservation 
of memory-modulating properties of the peptide across species (Bridge et al. 2003). A moderate 
to high expression of NOP receptors has also been demonstrated in principal cells of the DG, 
CA1 and CA3 in the human brain (Berthele et al. 2003). Polymorphisms or changes in NOP 
receptor expression have been associated with various neuropsychiatric conditions in human 
such as PTSD (Andero et al. 2013), alcohol dependence (Huang et al. 2008), opiate addiction 
(Briant et al. 2010) and suicide (Lutz et al. 2015) but, so far, not with pathologies characterized 
by deficits in learning and memory. Based on the preclinical data, one might suggest that NOP 
agonists could be useful as amnestic drugs for disorders associated with maladaptive memories 
such as PTSD and addiction. This hope, however, must be tempered by the fact that NOP 
agonists can be predicted to interfere more efficiently with hippocampus-dependent episodic 
memories than amygdala-dependent emotional memories. It is also important to note that, 
although several clinical trials have been performed, no NOP-selective agonist has been 
advanced into phase II (cebranopadol, a phase III analgesic compound is a mixed NOP-MOP 
agonist) (Zaveri 2016), one main concern being the narrow therapeutic window before sedative 
effects are observed in patients. More promising may be the use of NOP antagonists as memory 
enhancers. A recent study reported the NOP antagonist LY2940094 to be safe and well tolerated 
and  to show some efficacy in reducing symptoms of depression in Major Depressive Disorder 
patients (Post et al. 2016). Another phase II study is underway with a higher dosage of the 
compound for the same pathology (ClinicalTrials.gov Identifier: NCT03193398). Provided that 
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the promnesic properties of NOP antagonists are better characterized in preclinical models, it 
seems therefore realistic to envision testing such molecules in the future to improve learning 
and memory in patients suffering from cognitive deficits associated with neuropsychiatric or 
neurodegenerative diseases. 
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Table 1 
Name Description of the task References 
Morris Water Maze 
(MWM) 
Used to assess spatial memory. The mouse is 
placed in a pool of water where it must learn to 
use spatial cues located in the room to navigate 
to a submerged platform. The time to reach the 
platform decreases across trials and during the 
probe test, when the platform is removed, 
animals spend more time in the quadrant where 
the platform was located. The visible platform 
version of the test allows to assess non spatial 
components such as swimming ability and 
procedural memory. 
(Higgins et al. 2002; 
Koster et al. 1999; 
Kuzmin et al. 2009; 
Manabe et al. 1998; 
Redrobe et al. 2000; 
Sandin et al. 1997; 
Sandin et al. 2004)  
Fear Conditioning 
(FC) 
Used to assess aversive associative memory. It is 
a form of Pavlovian conditioning based on the 
association of an aversive stimulus (an electric 
shock) with a conditioned stimulus, the context 
in which the shock was received (Contextual 
FC), or a discrete cue such as a sound (Tone FC). 
During the retention test, the freezing behavior 
(conditioned response) triggered by the 
presentation of the context or the sound is 
measured. 
(Andero et al. 2013; 
Fornari et al. 2008; 
Goeldner et al. 2009; 
Mamiya et al. 2003; 
Ouagazzal 2015; 
Rekik et al. 2017)  
Inhibitory Avoidance 
(IA) 
Used to assess aversive associative memory. 
Also called Passive Avoidance. The mouse 
receives a foot shock when it enters a dark 
compartment (step-through version) or steps 
down a platform (step-down version). During the 
retention test, the animal has to inhibit its natural 
tendency to enter the secure dark environment or 
leave the aversive platform. If it remembers 
receiving the electric shock the step-through or 
step-down latency should increase. 
(Adem et al. 2017; 
Hiramatsu and Inoue 
1999; 2000; 
Hiramatsu et al. 
2008; Liu et al. 
2007; Manabe et al. 
1998; Miwa et al. 
2009; Miwa et al. 
2010; Roozendaal et 
al. 2007)  
Object Recognition 
(OR) 
Used to assess recognition memory. During the 
learning phase the mouse is allowed to explore 
two identical objects in an open field. During the 
test phase, one of the object is replaced by a new 
one. If the animal detects the change, and thus 
recognize only the familiar object, it will spend 
more time exploring the new one. 
(Goeldner et al. 
2008) 
Y-maze, spontaneous 
alternation 
Used to assess spatial working memory. The 
mouse is put in the center of a Y-maze and 
allowed to explore it freely without any reward. 
If its spatial working memory is intact an animal 
is supposed to alternate regularly between the 
three arms in order to optimize its exploration 
strategy.  
(Hiramatsu and 
Inoue 1999; 2000; 
Mamiya et al. 1999; 
Miwa et al. 2009; 
Ouagazzal 2015) 
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Table 1: Main behavioral paradigms used to assess the memory modulating properties of the 
N/OFQ system. 
 
 
 
 
 
